Top Medical News
23 hours ago
Longitudinal trajectories in body mass index (BMI) may be predictive of new-onset diabetes, a recent study has found.
Yesterday
Dietary flaxseed and tamoxifen both affect normal breast tissue in vivo, a study has shown, adding that a relatively modest change in the diet can lead to significant effects on the breast microenvironment.
Roshini Claire Anthony, 2 days ago

Combining high-dose teriparatide with denosumab may improve areal bone mineral density (aBMD) in postmenopausal women with osteoporosis, according to results of the phase IV DATA-HD* study.

Pearl Toh, 3 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
3 days ago
Type 2 diabetes (T2D) is an independent risk factor for all-cause dementia, with the greatest risk observed in patients who are insulin-dependent and obese, a recent study has found.
Roshini Claire Anthony, 3 days ago

Weight- and blood pressure (BP) management strategies could promote the reversion from prediabetes to normoglycaemia, according to results of the SNAC-K* study.

Roshini Claire Anthony, 4 days ago

A newly developed clinical risk score can identify patients with type 2 diabetes (T2D) at greatest risk for hospitalization for heart failure (HHF) who would derive the most benefit from treatment with dapagliflozin, according to a study presented at ESC 2019.

Special Reports
11 Sep 2019
At the recent 10th Malaysian Endocrine and Metabolic Society (MEMS) Annual Congress(MAC) held in Hilton Kuala Lumpur, Dr Wong Ming, a consultant endocrinologist from Sunway Medical Centre, spoke on the role of non–high-density lipoprotein cholesterol (non–HDL-c) as an emerging marker and treatment target for cardiovascular (CV) disease. Additionally, she also highlighted the role of fenofibrate in delaying and preventing diabetic retinopathy (DR).
02 May 2019
At a recent Abbott lunch symposium held in conjunction with the joint 12th International Diabetes FederationWestern Pacific Region Congress & 10th Asian Association for the Study of Diabetes Scientific Meeting in KualaLumpur, Professor Shashank R. Joshi extensively discussed the issue of diabetes in obesity and the role of nutritionalintervention in addressing this growing problem.
24 Apr 2019
At the recent 12th IDF-WPR Congress and 10th AASD Scientific Meeting held at Kuala Lumpur Convention Centre, the importance of glycaemic control and the practical management of type 2 diabetes mellitus (T2DM) were highlighted by two international speakers, Dr Sanjay Kalra from India and Professor Jean Claude Mbanya from Cameroon.
29 Mar 2019
Dapagliflozin 5 mg and 10 mg FC tab
28 Nov 2018
At the Abbott-sponsored symposium held during the 9th Malaysian Endocrine and Metabolic Society Annual Congres sat Hilton Kuala Lumpur, Dr Zanariah Hussein shared her insights into the important role of an emerging marker of hypercholesterolaemia, and its relationship with cardiovascular (CV) and diabetic retinopathy (DR) risks.
21 Nov 2018
At the AstraZeneca-sponsored symposium held during the 9th Malaysian Endocrine and Metabolic Society Annual Congress at Hilton Kuala Lumpur, Professor Ronald Ma highlighted the role of a novel combination therapy in reducing HbA1c levels while simultaneously providing cardiovascular (CV) protection to improve patient outcomes.
Dr. Robert Giugliano, Prof. Ulrich Laufs, Prof. Gaetano De Ferrari, Prof. Naveed Sattar, 11 Oct 2018

The FOURIER trial previously demonstrated that adding the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab to background statin therapy lowered LDL-cholesterol (LDL-C) below target levels and significantly reduced the risks of cardiovascular (CV) events in patients with atherosclerotic cardiovascular disease (ASCVD). At the European Society of Cardiology (ESC) Congress 2018 in Munich, Germany, experts reiterated how evolocumab helps lower LDL-C levels and reduces CV events even in patients with various comorbidities.

Conference Reports
Roshini Claire Anthony, 16 Sep 2019

A newly developed clinical risk score can identify patients with type 2 diabetes (T2D) at greatest risk for hospitalization for heart failure (HHF) who would derive the most benefit from treatment with dapagliflozin, according to a study presented at ESC 2019.

16 Sep 2019
Prof Deepak Bhatt gives a rundown of the findings from THEMIS and THEMIS-PCI
16 Sep 2019
Podcast: Prof Derek Chew explains the importance of a 1-hour troponin T protocol in suspected ACS as discussed in the RAPID-TnT trial
15 Sep 2019
Podcast: Dr Shamir Mehta briefly discusses the clinical impact of findings from the COMPLETE trial
Audrey Abella, 11 Sep 2019
The addition of ticagrelor to aspirin significantly reduced ischaemic events but led to an upsurge in major bleeding events relative to aspirin alone in individuals with stable coronary artery disease (CAD) and type 2 diabetes (T2D) without prior myocardial infarction (MI) or stroke. However, there was a favourable net clinical benefit in a subgroup with prior percutaneous coronary intervention (PCI), according to the results of the THEMIS* and THEMIS-PCI trials presented at the ESC Congress 2019.
Pearl Toh, 06 Sep 2019
Dapagliflozin consistently reduced the composite outcome of cardiovascular (CV) death and HHF* in patients with type 2 diabetes (T2D) regardless of kidney function, with the greatest benefit seen in those with both reduced eGFR and albuminuria, new insights from the DECLARE-TIMI 58 trial revealed.
04 Sep 2019
Slideshow: Highlights from the European Society of Cardiology (ESC) Congress 2019 & World Congress of Cardiology (WCC) 2019
CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download